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Background. The treatment of pancreatic cancer and other periampullary neoplasms is complex and challenging. Major high-
volume cancer centers can provide excellent multidisciplinary care of these patients but almost two-thirds of pancreatic cancer
patients are treated at low volume centers. There is very little published data from low volume community cancer programs in
regards to the treatment of periampullary cancer. In this study, a review of comprehensive periampullary cancer care at two low
volume hospitals with comparison to national standards is presented. Methods. This is a retrospective review of 70 consecutive
patients with periampullary neoplasms who underwent surgery over a 5-year period (2006–2010) at two community hospitals.
Results. There were 51 successful resections of 70 explorations (73%) including 34 Whipple procedures. Mortality rate was 2.9%.
Comparison of these patients to national standards was made in terms of operative mortality, resectability rate, administration
of adjuvant therapy, clinical trial participation and overall survival. The results in these patients were comparable to national
standards.Conclusions.Withadequatecommitmentofresourcesandexperiencedsurgicalandoncologicpractitioners,community
cancer centers can meet national tertiary care standards in terms of pancreatic and periampullary cancer care.
1.Introduction
Pancreatic adenocarcinoma is the 4th leading cause of cancer
death in the United States. The National Cancer Institute
estimated that there were 43,140 new cases of pancreatic
cancerintheUnitedStatesin2010andthatpancreaticcancer
was responsible for 36,800 deaths [1]. Other periampullary
malignancies requiring similar treatment are less common
and include distal common bile duct cancer, duodenal
cancer, and ampullary cancer. Standard of care treatment of
thesecancersandespeciallypancreaticcancerrequiresamul-
tidisciplinary approach and many components of treatment
require special expertise, that is, biliary-pancreatic surgery,
endoscopy, and radiology.
High-volume tertiary care centers and cancer institu-
tions have greatly advanced the care of pancreatic cancer
patients over the last 4 decades, and there are a number
of studies indicating the superior surgical results [2–5]a n d
possibly long-term survival [6] for patients cared for at
such facilities. Nevertheless, it is impossible for all pancreatic2 International Journal of Surgical Oncology
cancer patients to be cared for at regional cancer centers
and a signiﬁcant number of patients receive their pancreatic
cancer care at community institutions [7]. Some studies note
t h a tv o l u m ei sa ni m p e r f e c ts u r r o g a t ef o rq u a l i t ya tb e s t
[8].Low-andmedium-volumecenterscandeﬁnitelyprovide
excellent complex cancer care given adequate resources and
experienced practitioners [9]. Many patients and families
desire to have their cancer care at local facilities for various
reasons [10]. These include the burden of travel and lodging
at out-of-town institutions as opposed to the familiarity and
easier access to local physicians and hospitals. Consequently,
it is desirable to have standard of care pancreatic cancer
treatment at community medical facilities where practical.
This paper describes the introduction of pancreatic sur-
geryattwomedicalcentersinOgden,WeberCounty,Utah—
McKay-Dee Hospital Center (MKD) and Ogden Regional
Medical Center (ORMC), and the results of the subsequent
multidisciplinary care of pancreatic and other periampullary
cancer patients. Prior to the introduction of pancreatic
surgery in Weber County in August, 2006, the vast majority
of pancreatic cancer patients in this area were referred to Salt
Lake City, some 40 miles away.
2.Materials
We retrospectively reviewed all patients (70) who underwent
resection of pancreatic adenocarcinoma, other pancreatic
and periampullary neoplasms or palliative surgery for unre-
sectable periampullary cancer over a 4.5-year period begin-
ning in August 2006 at MKD and beginning in January 2008
at ORMC. It was at this time that one of the authors with
experience in pancreatic surgery (RCM) joined the staﬀso f
the two hospitals in Ogden, UT. Our retrospective review
includes patient pathologies, surgical results, adjuvant ther-
apies, and survival. Additionally, patient survival, through
December 2010, for pancreatic cancer was compared stage
for stage to the results documented in the National Cancer
Data Base (NCDB) of the American College of Surgeons
Commission on Cancer [11]. Results and basic descriptive
statistics are presented.
3.GeographicAreaServed
Utah, the 13th largest state in the United States, is a large (84,
904squaremiles)[12],mostlyruralstatewithasingle“strip”
of urban demographics covering 4 counties (Weber, Davis,
Salt Lake and Utah) in northern Utah with Salt Lake City
at the center of this urban “strip.” These 4 counties, known
as the “Wasatch Front” as they run between the Wasatch
Mountains and the Great Salt Lake, contain 76% of Utah’s
population. (2,785,000—2009 estimate) [13].
Pancreatic cancer in Utah (2003–2007 data) has an inci-
dence of 9.7 per 100,000 with an annual mortality rate of
8.9 per 100,000. This translates to about 250 cases per year
and a total of 220 deaths per year in Utah [14]. Prior to
2006,radiationandchemotherapyforpancreaticcancerwere
delivered at a number of medical centers around the state,
but almost all pancreatic cancer surgical care, particularly
Whipple procedures, was delivered in Salt Lake City, mostly
at either the University of Utah Medical Center or LDS
Hospital. A handful of pancreatic cancer surgeries are also
done at other hospitals in Salt Lake City as well as in Provo
and St. George. Clearly another center for the delivery of
comprehensive pancreatic cancer care was highly desirable,
see Figure 1.
4.McKay-DeeHospitalCenter
McKay-Dee Hospital Center, owned by Intermountain
Healthcare, is a 317-bed community hospital which provides
comprehensive medical and surgical care [15]. Located in
Ogden,Utah(2006population78,100[13]),itservespatients
primarily in Weber, Morgan, and northern Davis Counties
(2009 populations 232,000, 8,900, and 301,000, resp.) [13]
in northern Utah. However, it serves as a tertiary referral
center and draws patients from a vast geographic area
including all of northern Utah, north of Salt Lake City, as
well as southwestern Wyoming and southeastern Idaho. It
has an American College of Surgeons Committee on Cancer
accredited cancer program.
5. Ogden Regional Medical Center
Ogden Regional Medical Center [16], owned by Moun-
tainStar, is a 238-bed community hospital which provides
comprehensive medical and surgical care to the same region
asMcKay-DeeHospital.Theyare,infact,2.5milesapart,and
they are the only hospitals in Weber County.
6. Patient Management
Both facilities have a well-functioning cancer committee for
presentation and discussion of complex patients. Most of the
pancreatic cancer patients are seen in a multidisciplinary GI
cancerclinictofacilitatepatientcareandtreatmentplanning.
Biliary endoscopy, diagnostic and interventional GI radiol-
ogy, state-of-the-art surgical care, and full-time intensivists
are available at both facilities.
Radiation therapy at both facilities is based on state of
the art treatment guidelines. Three-dimensional conformal
or IMRT radiation therapy techniques are utilized, with no
fewer than four to seven treatment angles. Dose to the
prescribed volume is generally 4500cGy, followed by a con-
edown boost to the tumor bed or unresected tumor and
margin for an additional 540 to 900cGy. Dose volume his-
togramsareusedtoanalyzedosetothemultiplesurrounding
normal structures, including the liver, kidneys, small bowel,
and spinal cord. Multiple plans are tried, with or without
couch angles, to minimize dose to normal structures.
Administration of chemotherapy generally consists of
intravenous gemcitabine (Gemzar) 1000mg on days 1, 8, 15,
21, and 28. Then after concurrent radiation with continu-
ous infusion 5-Fluorouracil (5-FU) 250mg/m2, intravenous
gemcitabine is continued 1000mg on days 1, 8, 15 every four
weeks for three to six months.International Journal of Surgical Oncology 3
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Figure 1: State of Utah, with counties and select cities indicated.
7. Results
Over the 4.5 years of this review, a total of 70 pancreatic
resections were performed or attempted by a single surgeon
(RCM). These included 34 resected cancers, 17 resections
for benign disease, and 19 palliative procedures. The most
common pathology was pancreatic adenocarcinoma with 28
resected adenocarcinomas and 16 unresectable adenocarci-
nomas for a total of 44 surgical pancreatic cancer patients.
The unresectable adenocarcinomas included 10 metastatic
lesions and 6 locally advanced lesions with extensive vascular
involvement. The pathologies for the resected cancers, the
benign lesions, and the palliative procedures are summarized
in Figures 2, 3,a n d4,r e s p e c t i v e l y .
The procedures performed included 26 pylorus-preserv-
ing Whipple procedures, 7 classic Whipples, 12 distal pan-
createctomies, 1 total pancreatectomy, 1 middle-segment
pancreatectomy, and 4 enucleations. The 19 palliative pro-
cedures included 11 gastrojejunostomies, 6 combined gas-
trojejunostomies and hepaticojejunostomies, 1 laparoscopic
liver biopsy, and 1 pancreas-sparing partial duodenectomy.
(This was for a bleeding duodenal cancer in a patient with
metastatic disease.) An alcohol neurolysis of the splanchnic
nerves was usually performed with the open palliative pro-
cedures. There were two 30-day mortalities (2.9%). Among
the patients with pancreatic adenocarcinoma (44), there was
one operative mortality (2.3%). Among patients who had
Whipple procedures (34), there was one operative mortality
(2.9%), and the mortality rate was 2% (1 of 51) for all pan-
creatic resections.
Of the 28 resected pancreatic adenocarcinomas, 24 pa-
tients (86%) completed a full course of radiation therapy,
most of which also had concurrent continuous infusion 5-
FU. Of these, one was in a neoadjuvant setting prior to
resection of a pancreatic body lesion. Of the 4 patients who
did not receive a full course of radiation therapy, one
declined all adjuvant therapy; one stopped therapy due to
side eﬀects; one was on the RTOG 0848 [17]p r o t o c o la n d
was randomized to no radiation therapy, and one developed
metastasis prior to planned radiotherapy and therefore did
not proceed. Of the 6 patients with locally advanced (not
metastatic) disease, one had a full course of chemoradiation
in the neoadjuvant setting, but remained unresectable at
exploration. Two had a full course of chemoradiation
after exploration. Two had incomplete radiotherapy due to
intolerance, and one was lost to followup.4 International Journal of Surgical Oncology
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Figure 2: Resected Cancers (n = 34).
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Figure 3: Benign Lesions (n = 17). ∗This patient had a mass in the tail of the pancreas on CT with an elevated CA 19-9 which resolved after
distal pancreatectomy, but no clear adenocarcinoma could be conﬁrmed on pathology.
In terms of adjuvant chemotherapy, 26 (93%) of the pa-
tients with resected adenocarcinomas received gemcitabine-
(Gemzar-) based chemotherapy. The other two patients
declined chemotherapy. Two of the 26 received Gemzar in
the neoadjuvant setting. Four of the 26 received Gemzar in
combination with other agents including Xeloda, Avastin,
Tarceva, and Erlotinib. All of these patients were on study
protocols. Of the unresected patients, nine patients re-
ceived Gemzar chemotherapy, four of which also received
other agents (Xeloda, Oxaliplatin, Erlotinib, FOLFOX). Two
patients declined chemotherapy. Two received 5-FU with
radiation but no further chemotherapy. Three were lost to
follow up. Two of the patients received neoadjuvant chem-
otherapy (one with radiation as well) but remained unre-
sectable at exploration.
Of the 44 patients with pancreatic adenocarcinoma, six
(14%) participated in a clinical trial, ﬁve at McKay-Dee Hos-
pital, and one at the University of Utah. These clinical trials
included RTOG 0848 [17], E2204 [18], and SWOG 0727
[19].International Journal of Surgical Oncology 5
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Figure 4: Unresectable Cancers (n = 19).
Table 1: Survival in resected pancreatic cancer patients. A “potential” survivor is one whose surgery was done long enough ago to be a
possible survivor for the indicated number of years.
Total Patients Potential 1-year
survivors
Actual 1-year
survivors
Potential 2-year
survivors
Actual 2-year
survivors
Potential 3-year
survivors
Actual 3-year
survivors
All resected patients∗ 28 21 18 (86%) 13 8 (62%) 8 2 (25%)
Stage I patients 8 7 7 (100%) 2 2 (100%) 1 1 (100%)
Stage II patients 19 13 10 (77%) 10 5 (50%) 7 1 (14%)
∗Included in this group is the patient who presented with Stage III disease but was downstaged with neoadjuvant therapy and resected.
8.Survival
The median followup for all 44 pancreatic cancer patients
is 9 months. For those patients still living (25), the median
followup is 10 months. For the 10 patients with metastatic
(Stage IV) pancreatic cancer, 7 are dead with an average sur-
vivalof6.6months.Forthesixpatientswithlocallyadvanced
pancreatic cancer (Stage III), three are dead with an average
survival of 5 months. The six remaining unresected patients
remain alive 1–10 months after their surgery. An additional
patient who presented with Stage III disease underwent
neoadjuvant chemo- and radiation therapy followed by a
distal pancreatectomy and splenectomy and is alive at 27
months.
For the 28 resected pancreatic cancers, the median sur-
vivalhasnotyetbeenreachedwith19stillliving.Theaverage
survival for those still living is 18 months (range 4–49).
The average survival for those patients who have died is
17 months (range 4–32). Actual 1-, 2-, and 3-year survival
is demonstrated in Table 1. Overall, 86% of patients (18 of
21) who are at least one year postsurgery have survived one
year, and 62% of patients (8 of 13) who are at least two
years postsurgery have survived two years. Comparison to
National Cancer Data Base results is illustrative: 1-year, 2-
year and 3-year survivals for Stage I disease are 47%, 28%,
and 21%, respectively. For Stage II disease the 1-year, 2-year
and 3-year survivals are 50%, 26%, and 16%, respectively
[11].
9. Discussion
This review demonstrates the results of the introduction of
pancreatic surgery and multidisciplinary pancreatic cancer
care at two community hospitals over a 4.5-year period.
This introduction proceeded smoothly in large part due to
excellent oncologic and gastroenterologic resources already
in place. Very active cancer committees and administrative
support facilitated this process.
Published series of pancreatic cancer experience from
low-volume community centers are few [9, 20, 21] despite
the fact that low-volume centers take care of the majority
of these patients—61%, based on the Chang review of
Nationwide Inpatient Sample data [7]. It is clear that quality
and outcomes can vary considerably at low volume centers.
Nevertheless,ourdataaswellasotherssupporttheideathata
community facility with adequate resources and experienced
practitioners can provide very-high-quality comprehensive
pancreatic cancer care.
Pancreatic surgery in a community setting has some
unique challenges. Pancreatic surgery requires an experi-
encedsurgeonanda skilled surgicalassistantduring much of6 International Journal of Surgical Oncology
the procedure. At academic and large community hospitals,
surgical residents provide the skilled assistance necessary.
Surgical residents from the University of Utah (BH and CJ)
occasionally electively rotate at our hospitals and assisted
on about 25 of these procedures. A certiﬁed nurse ﬁrst
assistant (JD) assisted on the majority of these procedures
with other assistance from surgical partners where necessary.
Additionally, in the absence of 24-hour surgical resident in-
house availability, the 24-hour availability of hospitalists and
intensivists at our facilities to provide critical care and urgent
“rescue care” has been important.
Our relatively small numbers make any true statistical
analysis impossible and irrelevant. However, our results can
at least be assessed and understood in light of available
national outcomes data and benchmarks. On this basis,
our results are clearly acceptable when compared to large
published series and databases. Our operative mortality was
2.9% for pancreatic procedures in general (2 of 70) and
Whipple procedures speciﬁcally (1 of 34). This is consistent
with other published series, even those with much higher
volume. In the paper by Gordon et al. [2], in 1995, looking
at volume of Whipple procedures and hospital mortality
in Maryland (1988–93 data), the hospital with the highest
volume had a mortality rate of 2.2%. Our series averaged 8
Whipples per year, which would be in the 4th of 5 quintiles
described in that study. That group of hospitals had a
mortalityrateof14.3%,comparedtowhich,weareobviously
very favorable. In a follow-up study of 1990–1995 Maryland
State data which considered both Whipples and palliative
procedures, Sosa et al. [3] stratiﬁed hospitals into low- (1–4),
medium- (5–19), and high-volume (20 or more) procedures
forpancreaticcancer.Inourseries,weaveraged16pancreatic
surgeriesperyearwhichwouldputusinthemediumvolume
category. The mortality for pancreatic cancer resections and
palliative bypasses at the medium volume hospitals in the
Sosa study was 7% and 11%, respectively, compared to our
mortality rate of 2% and 5% for the same categories. In the
highest volume hospitals in the Sosa study, the respective
mortality rates were 1% and 4%. In the Birkmeyer study
which considered national Medicare data from 1994–1999
[5], the very highest volume hospitals (> than 16 pancreatic
resections per year) had a mortality rate of 3.8%.
Another paper by Birkmeyer et al. [22] analyzed indi-
vidual surgeon volume for a number of complex proce-
dures including pancreatic resection. They analyzed Medi-
care claims data for 1998-1999 and stratiﬁed surgeons into
low-, medium-, and high-volume groups. For pancreatic
resection, 30-day mortality was 14.7%, 8.5%, and 4.6% for
the three groups, respectively. The authors’ deﬁnition of high
volume in this paper was greater than 4 pancreatic resections
per year. Thus, the surgeon in our paper would be stratiﬁed
as a high-volume surgeon, and our 30-day operative mortal-
ity rate of 2.9% would be acceptable.
In terms of adjuvant therapy, our delivery of appropriate
adjuvant chemo- and radiation therapy to 93% and 86%
of eligible patients, respectively, is consistent with national
standards. In fact, population-based studies by Davila et al.
[23] and Birkmeyer et al. [6]o fS E E R - M e d i c a r ed a t af r o m
1992–2002 demonstrated that only 49% of patients received
adjuvant therapy after surgery. Diﬀerences between low- and
high-volume centers were also seen, varying from 21% to
52% from low to high volume centers.
Nationally, participation in cancer clinical trials is 2–4%
[24]. By comparison, we placed 14% of our patients into
clinical trials in both adjuvant and palliative settings. Where
patients are treated in local facilities with minimal travel
burden, participation in clinical trials may well be more
appealing to patients and families.
In our series, ten of 44 patients (23%) had unexpected
metastatic disease at the time of exploration, and six pa-
tients (14%) had vascular involvement that precluded resec-
tion for a total unresectability rate of 36%. These results
are comparable to typical published series including Mas-
sachusetts General Hospital [25], where the rate of unex-
pected metastatic disease was eight of 44 (18%) and 13
patients (30%) had vascular involvement for a total unre-
sectability rate of 48% and University of Maryland [26]
wheretherateofunexpectedmetastaticdiseasewas27of101
(27%) and the rate of and 16 patients (16%) had vascular
involvement for a total unresectability rate of 43%.
Overall survival, as well as survival by stage, remains
diﬃcult to compare because of our small numbers and 5-
year survival is obviously unavailable as our experience only
extends4.5years.Nevertheless,comparedtoNCDBdata,our
survival is clearly noninferior to these national data and
may well be above average for one- and two-year survival.
Our results are also comparable with typical large single
institution series [27].
The issue of the degree to which case volume inﬂuences
outcomes in complex illnesses of all types and especially
complex cancer surgery is important, and exhaustive data
analyses have been done. The references [2–8] cited in this
review are just a small sample of the available literature,
but are speciﬁc for pancreatic cancer. These reviews and
other large single-institution series have set clear outcome
benchmarks that should be achievable by centers (large or
small) seeking to provide comprehensive pancreatic cancer
care. By every standard reported in this review—operative
mortality, resectability rate, adjuvant chemo, and radiation
therapy, participation in clinical trials, and overall survival,
comparability to national tertiary care benchmarks has been
achieved, even taking into consideration small numbers and
a total experience of less than 5 years.
There are a number of reasons that increasing the
number of high-quality comprehensive community cancer
facilities is desirable. Many patients, perhaps the majority,
cannot or will not go to high-volume academic or regional
cancer centers [7]. One of the implications of this is that
a signiﬁcant number of patients are not oﬀered and do
not receive potentially curative surgical therapy. This is well
documented by Bilimoria et al. who used NCDB 1995–
2004 data to demonstrate that 38% of potentially resectable
patients were not oﬀered surgery [28]. Tragically, their data
also show that medically vulnerable patients—those over 65,
black,MedicareorMedicaid,lesseducated,andlessaﬄuent–
are overrepresented in this group. A second important issue
is also demonstrated by Bilimoria’s group. They used 1995–
2005 NCDB data to demonstrate that wait times fromInternational Journal of Surgical Oncology 7
diagnosis to treatment of many cancers, including pancreas,
at NCI Comprehensive Cancer Centers and VA Hospitals
increased during that decade [29]. They note that with the
rising cancer burden in the US population this trend is likely
to continue. Finally, data clearly show that patients prefer
to be treated locally where possible. In fact many patients
prefer to be treated locally even if the local facility has a
demonstrably higher mortality rate than a regional center
[10]. For all of these reasons, it is highly desirable that,
where practical, community facilities and practitioners make
the necessary investment to provide comprehensive complex
cancer treatment.
10. Conclusions
This review documents the introduction of pancreatic sur-
gery and with it, comprehensive multidisciplinary care of
pancreaticcancer,totwocommunityhospitalsinwhosegeo-
graphic area such care was not previously available. Over a
4-year period, acceptable results, comparable to established
tertiary care standards, for operative mortality, resectability
rate, administration of adjuvant, and, where indicated, ne-
oadjuvant therapy, clinical trial participation, and overall
survival have been achieved.
Introduction of pancreatic surgery and providing multi-
disciplinary pancreatic cancer care is a resource-intense pro-
cess. Medical institutions making that commitment must
have full-time availability of biliary endoscopy, interven-
tional radiology, surgical and anesthesia expertise in pan-
creaticobiliary procedures, intensive care medicine, as well
as multidisciplinary oncologic treatment. Meeting the stan-
dards for Committee on Cancer Accreditation and imple-
menting NCCN guidelines by a multidisciplinary team of
practitioners and an active Cancer Committee are some of
the important keys that can enable a community hospital to
achieveexcellenceinpancreaticcancercare.Recognizingthat
judicious referral of extremely complex patients to regional
centers is necessary is also important [30].
Many have advocated regionalizing complex cancer care
in general and pancreatic cancer care speciﬁcally. The trend
toward moving at least some complex pancreatic cancer
away from low-volume centers is readily apparent [7]. Nev-
ertheless, community-based cancer centers, hospitals, and
physicians committed to providing complex cancer care
can provide excellent care in that regard, despite being
relatively low-volume centers. Such community centers are
very beneﬁcial to cancer patients in regards to the ability to
oﬀer more patients potentially curative therapies, reduce
travel burden, and reduce wait times for therapy. Experience,
commitment, and teamwork are as important as volume in
the care of pancreatic cancer patients.
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